Compare Stocks → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IFRXNASDAQ:KTOVNASDAQ:LUMONASDAQ:OASMNASDAQ:OBSV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIFRXInflaRx$1.38$1.52$1.14▼$5.20$81.25M1.26208,761 shs179,383 shsKTOVPurple Biotech$0.53-1.9%$4.16$2.20▼$14.40$8.33M2.371.18 million shs108,156 shsLUMOLumos Pharma$2.96-2.6%$2.83$2.41▼$4.55$24.04M0.6632,590 shs69,636 shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/AOBSVObsEva$0.01$0.01$0.08▼$2.14$390K0.688.94 million shs10,550 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIFRXInflaRx0.00%+3.76%-10.97%-14.81%-69.60%KTOVPurple Biotech-2.03%+8.16%-21.43%-27.40%-72.75%LUMOLumos Pharma-2.63%+4.78%+7.25%-1.00%-10.30%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%OBSVObsEva+2,400.00%0.00%-60.00%-91.67%-94.05%Investors Alert: The Next Big Thing in Weight Loss (Ad)UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year. Get the name of the stock here >>> MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIFRXInflaRx3.4805 of 5 stars3.85.00.00.02.01.71.3KTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/ALUMOLumos Pharma2.2191 of 5 stars3.51.00.00.00.02.51.3OASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIFRXInflaRx3.50Strong Buy$13.50878.26% UpsideKTOVPurple BiotechN/AN/AN/AN/ALUMOLumos Pharma3.00Buy$18.00508.11% UpsideOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/ACurrent Analyst RatingsLatest OBSV, IFRX, OASM, KTOV, and LUMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/20/2024LUMOLumos PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIFRXInflaRx$70K1,160.78N/AN/A$1.89 per share0.73KTOVPurple Biotech$1M8.33N/AN/A$5.56 per share0.10LUMOLumos Pharma$2.05M11.72N/AN/A$3.45 per share0.86OASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03OBSVObsEva$20.11M0.02N/AN/A$0.41 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/8/2024 (Confirmed)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ALUMOLumos Pharma-$34.03M-$4.19N/AN/AN/A-1,659.39%-85.63%-65.30%5/8/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/AOBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ALatest OBSV, IFRX, OASM, KTOV, and LUMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AIFRXInflaRx-$0.24N/A+$0.24N/AN/AN/A3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A3/7/2024Q4 2023LUMOLumos Pharma-$1.18-$1.17+$0.01-$1.17$0.01 million$0.83 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIFRXInflaRxN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/ALUMOLumos PharmaN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIFRXInflaRxN/A6.505.82KTOVPurple BiotechN/A2.22N/ALUMOLumos PharmaN/A5.695.69OASMOasmia Pharmaceutical AB (publ)N/A0.800.73OBSVObsEvaN/A0.610.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIFRXInflaRx42.39%KTOVPurple Biotech30.72%LUMOLumos Pharma33.99%OASMOasmia Pharmaceutical AB (publ)0.11%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipIFRXInflaRx16.30%KTOVPurple Biotech2.98%LUMOLumos Pharma25.40%OASMOasmia Pharmaceutical AB (publ)N/AOBSVObsEva14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIFRXInflaRx6258.88 million49.29 millionOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableLUMOLumos Pharma338.12 million6.06 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableOBSV, IFRX, OASM, KTOV, and LUMO HeadlinesSourceHeadlineObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 28 at 2:20 AMObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listinglobenewswire.com - April 3 at 1:00 AMObsEva Announces Update on Board of Directorsglobenewswire.com - March 19 at 2:00 AMObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023globenewswire.com - February 28 at 1:00 AMObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Datesbenzinga.com - February 26 at 12:34 AMObsEva SA OBSNmorningstar.com - November 11 at 10:37 PMObsEva SA OBSEFmorningstar.com - November 11 at 7:36 AMObsEva (NASDAQ: OBSV)fool.com - June 18 at 11:34 PMTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObservernews.google.com - May 10 at 1:37 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Financenews.google.com - May 2 at 1:32 PMObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaqnews.google.com - May 2 at 8:31 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswirenews.google.com - May 2 at 1:20 AMGameto Appoints Teri Loxam as Chief Financial Officer - citybiznews.google.com - April 28 at 11:20 PMObsEva Annual Report 2022 - Marketscreener.comnews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Yahoo Financenews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Benzinganews.google.com - April 28 at 1:20 PMObsEva Annual Report 2022 - EIN Newsnews.google.com - April 28 at 1:20 PMGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswirenews.google.com - April 28 at 8:19 AMEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journalnews.google.com - April 26 at 6:27 PMEndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPRnews.google.com - April 23 at 8:45 PMObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.comnews.google.com - April 21 at 3:44 PMObsEva Announces Change of Central Securities Depositary - Yahoo Financenews.google.com - April 20 at 11:41 PMObsEva Announces Change of Central Securities Depositary - GlobeNewswirenews.google.com - April 20 at 1:10 AMTackling Reproductive Health and Fertility Care - Pharmaceutical Executivenews.google.com - April 13 at 6:41 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Lumos PharmaNASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.